Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 MiMedx Completes Stability Biologics Acquisition - Orthopedic Design & Technology

What are you searching for?

Sign in
Financial/Business, OEM News

MiMedx Completes Stability Biologics Acquisition

Stability will operate as wholly owned subsidiary.

By: MiMedx Inc.

Marietta, Ga.-based MiMedx Group Inc., a regenerative medicine company, has completed the acquisition of Stability Inc., doing business as, Stability Biologics, a provider of human tissue products to surgeons, facilities and distributors serving the surgical, spine and orthopedics sectors of the healthcare industry.

Stability Biologics, which will operate as a wholly owned subsidiary of MiMedx, has developed an innovative proprietary platform in bioactive bone graft products and tissue allografts including structural/particulate bone, tendons/ligaments, structural allografts, demineralized bone matrix (DBM) and skin products for burns and traumatic wound care. Most recently, Stability Biologics introduced Physio, a unique bone grafting material comprised of 100 percent bone tissue with no added carrier, thus maximizing bone forming potential.

MiMedx affirmed its previously announced expectations for the transaction to be accretive to Full Year 2016 Adjusted EPS and its conservative projection for the 2016 Stability Biologics revenues from its processed tissue and bone product sales and distribution to be at least $15 million. The company also confirmed that the closing consideration for the transaction was $10 million paid at closing, comprised of 60 percent cash and 40 percent stock, plus assumed debt, with future contingent consideration to be paid through a two-year earn out arrangement based on the 2016 and 2017 performance of the Stability Biologics business. MiMedx affirmed that it still expects the earn-out to be the larger portion of the overall consideration for the transaction.

Add us as a preferred source on Google

Get the latest Orthopedic Design & Technology news, insights and analysis in your Google Search and AI experiences.

Add Orthopedic Design & Technology as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Orthopedic Design & Technology Newsletters

Topics